Catalyst Pharmaceuticals Inc
$ 24.35
-0.41%
26 Dec - close price
- Market Cap 2,992,916,000 USD
- Current Price $ 24.35
- High / Low $ 24.44 / 24.08
- Stock P/E 14.24
- Book Value 7.47
- EPS 1.71
- Next Earning Report 2026-03-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.18 %
- ROE 0.28 %
- 52 Week High 26.58
- 52 Week Low 19.05
About
Catalyst Pharmaceuticals, Inc. is a leading commercial-stage biopharmaceutical company based in Coral Gables, Florida, dedicated to the development and commercialization of novel therapies for rare neuromuscular and chronic neurological disorders. By focusing on high-impact treatments that address significant unmet medical needs, Catalyst aims to enhance the quality of life for patients afflicted by these often-overlooked conditions. The company's innovative approach and robust product pipeline position it favorably within the healthcare sector, making it a compelling investment opportunity for institutional investors interested in transformative advancements in rare disease therapeutics.
Analyst Target Price
$34.86
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-08 | 2023-08-09 | 2023-05-10 | 2023-03-15 |
| Reported EPS | 0.42 | 0.41 | 0.45 | 0.44 | 0.35 | 0.33 | 0.19 | 0.31 | -0.29 | 0.53 | 0.26 | 0.22 |
| Estimated EPS | 0.33 | 0.39 | 0.34 | 0.32 | 0.3 | 0.26 | 0.17 | 0.27 | -0.28 | 0.42 | 0.32 | 0.21 |
| Surprise | 0.09 | 0.02 | 0.11 | 0.12 | 0.05 | 0.07 | 0.02 | 0.04 | -0.01 | 0.11 | -0.06 | 0.01 |
| Surprise Percentage | 27.2727% | 5.1282% | 32.3529% | 37.5% | 16.6667% | 26.9231% | 11.7647% | 14.8148% | -3.5714% | 26.1905% | -18.75% | 4.7619% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.298 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CPRX
2025-12-24 14:10:56
Voya Investment Management LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 25.1% in the third quarter, now owning 446,399 shares valued at approximately $8.79 million. The biopharmaceutical company's board has also approved a $200 million share repurchase program, signaling management's belief that the stock is undervalued. Catalyst Pharmaceuticals has a consensus analyst "Buy" rating and a target price of around $32.67.
2025-12-24 10:10:56
Texas Permanent School Fund Corp significantly increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 178.8% in Q2, bringing its total to 67,934 shares valued at $1.47 million. This move is part of a broader trend of institutional investors, including Goldman Sachs and Bank of America, increasing their positions in the biopharmaceutical company, which has seen its institutional ownership reach 79.22%. Catalyst Pharmaceuticals has also authorized a $200 million share buyback program, and Wall Street analysts currently rate the stock as a "Buy" with an average price target of $32.67.
2025-12-23 13:09:27
Wedge Capital Management L L P NC has initiated a new position in Catalyst Pharmaceuticals (NASDAQ:CPRX) during the third quarter, acquiring 145,168 shares valued at approximately $2.86 million. This investment comes amid positive analyst sentiment, with an average "Buy" rating and a target price of $32.67 for the biopharmaceutical company. Catalyst Pharmaceuticals has also authorized a $200 million share repurchase program, indicating the board believes its shares are undervalued.
2025-12-23 04:09:27
Catalyst Pharmaceuticals Inc. stock underperformed its competitors on Wednesday, despite daily gains. The article briefly mentions Unity Software's fourth-quarter financial results, including a revenue increase of 35% year-over-year to $609 million and a quarterly loss of 66 cents per share. However, the full article content is restricted due to copyright issues.
2025-12-23 04:09:04
Toth Financial Advisory Corp significantly reduced its stake in Catalyst Pharmaceuticals (NASDAQ: CPRX) by 96.5% in Q3, now holding 2,150 shares valued at $42,000. Despite this, institutional ownership remains high at 79.22%, and analysts maintain an average "Buy" rating with an average target price of $32.67. Additionally, the company has approved a $200 million share repurchase program, indicating board confidence in the stock's value.
2025-12-22 16:09:04
Catalyst Pharmaceuticals (CPRX) has seen new options trading for the February 2026 expiration. A specific call contract at the $30.00 strike price offers a potential total return of 25.99% if the stock is called away, given a current share price of $23.93. The implied odds of this out-of-the-money contract expiring worthless are 84%, providing a 0.63% premium boost to investors.
